Hospital
Columbia Valley Healthcare System, L.P.
Columbia Valley Healthcare System, L.P. was paid $8.43M by Medicaid between Mar 2019 and Dec 2024, across 92 billing codes. Its largest line is 99284, emergency room visit (serious) — 39% of everything it billed.
33Billing provider infoCOLUMBIA VALLEY HEALTHCARE SYSTEM, L.P.
BROWNSVILLE, TX 78526
BROWNSVILLE, TX 78526
33aNPI1043267701assigned 05/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.43M
24GClaims157,899
24DCodes billed92
24AFirst – last monthMar 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#18 of 109
Median peer was paid$1.15M
This provider vs. median7.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 37 | $27.10 | |
| 2020 | 2,012 | $110K | |
| 2021 | 28,035 | $1.37M | |
| 2022 | 45,660 | $2.13M | |
| 2023 | 52,255 | $3.05M | |
| 2024incomplete | 29,900 | $1.77M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 39% | 13,833 | 13,118 | $3.25M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 15,972 | 15,464 | $1.76M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.1% | 5,530 | 5,154 | $347K |
| 80053 | Comprehensive metabolic panel | 3.7% | 7,142 | 6,513 | $310K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 2.5% | 1,255 | 1,121 | $211K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.2% | 8,496 | 7,654 | $183K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 1,610 | 1,464 | $173K |
| 85027 | 2.0% | 19,848 | 17,729 | $165K | |
| 71045 | Radiologic examination, chest; single view | 1.8% | 7,587 | 7,248 | $151K |
| 87400 | 1.7% | 5,765 | 5,602 | $146K | |
| J3490 | Unclassified drugs | 1.7% | 383 | 266 | $143K |
| 80305 | 1.6% | 1,863 | 1,754 | $132K |
80 more codes
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.3% | 4,151 | $112K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 1,000 | $106K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.1% | 5,168 | $96K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 1,049 | $94K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 771 | $93K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 1,380 | $88K |
| 76819 | Fetal biophysical profile; without non-stress testing | 1.0% | 656 | $87K |
| 80061 | Lipid panel | 1.0% | 805 | $86K |
| 82746 | <1% | 798 | $65K | |
| 82607 | <1% | 839 | $64K | |
| 80076 | <1% | 3,000 | $51K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 84 | $49K |
| 76801 | <1% | 414 | $34K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 277 | $30K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 14 | $28K |
| 86756 | <1% | 1,017 | $27K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 664 | $27K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,093 | $25K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 971 | $25K |
| 81025 | <1% | 1,361 | $22K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 667 | $21K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $18K |
| 83690 | <1% | 4,473 | $17K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 438 | $17K |
| 81003 | <1% | 2,542 | $16K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 92 | $15K |
| 30140 | <1% | 53 | $15K | |
| 86850 | <1% | 792 | $14K | |
| 84702 | <1% | 1,001 | $9K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,980 | $9K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 359 | $9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 42 | $8K |
| 82248 | <1% | 1,716 | $7K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 182 | $6K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 68 | $6K |
| 82247 | <1% | 223 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 94 | $5K |
| 84484 | <1% | 2,389 | $5K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 67 | $5K |
| 87088 | <1% | 860 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 186 | $4K |
| 85610 | <1% | 2,015 | $3K | |
| 85730 | <1% | 1,930 | $3K | |
| 86901 | <1% | 1,449 | $3K | |
| 86900 | <1% | 1,450 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 454 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,873 | $2K |
| 83880 | <1% | 870 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,938 | $1K |
| 76641 | <1% | 15 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 780 | $834.80 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 95 | $783.65 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 338 | $705.75 |
| 83605 | <1% | 700 | $672.42 | |
| 74018 | <1% | 12 | $565.95 | |
| 87077 | <1% | 217 | $537.13 | |
| 82652 | <1% | 30 | $525.42 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 175 | $485.54 |
| 87040 | <1% | 301 | $302.65 | |
| 87430 | <1% | 13 | $185.70 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 118 | $156.97 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 876 | $149.44 |
| 87186 | <1% | 96 | $124.52 | |
| 84703 | <1% | 54 | $119.86 | |
| 83735 | <1% | 135 | $99.55 | |
| 77080 | <1% | 12 | $73.91 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 48 | $52.10 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 379 | $50.26 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 145 | $42.58 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 25 | $40.25 |
| J2704 | Injection, propofol, 10 mg | <1% | 69 | $19.91 |
| A9270 | Non-covered item or service | 0% | 1,740 | $0.00 |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 0% | 20 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 16 | $0.00 |
| C1769 | Guide wire | 0% | 12 | $0.00 |
| 80320 | 0% | 12 | $0.00 | |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 376 | $0.00 |
| 82565 | 0% | 13 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 52 | $0.00 |
| 84520 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPUENTE, DANIEL (CFO)